Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2006International Journal of Medical SciencesOpen Access

PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJoseph Angel De Soto
Chu‐Xia Deng
Chu‐Xia DengDartmouth College

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Soto et al. (2006) studied this question.

synapsesocial.com/papers/6a64e6bbfac10bc8e2c6c3c6https://doi.org/10.7150/ijms.3.117
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG143612004 · 490 citations
  2. 2Tumor formation in Brca1 conditional mutant mice2002 · 61 citations
  3. 3Roles of BRCA1 in DNA damage repair: a link between development and cancer2003 · 172 citations
  4. 4Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform2003 · 297 citations
  5. 5Efficient Deletion of Normal Brca2-Deficient Intestinal Epithelium by Poly(ADP-Ribose) Polymerase Inhibition Models Potential Prophylactic Therapy2005 · 59 citations